These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8736239)

  • 21. A 5-year immunization field trial against hepatitis B using a Chinese hamster ovary cell recombinant vaccine in French Polynesian newborns: results at 3 years.
    Moulia-Pelat JP; Spiegel A; Martin PM; Cardines R; Boutin JP; Roux JF; Excler JL; Saliou P
    Vaccine; 1994 May; 12(6):499-502. PubMed ID: 8036822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in small infants: a randomized, double-blind comparative study.
    Sapru A; Kulkarni PS; Bhave S; Bavdekar A; Naik SS; Pandit AN
    J Trop Pediatr; 2007 Oct; 53(5):303-7. PubMed ID: 17478542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and safety in newborns of a new recombinant hepatitis B vaccine containing the S and pre-S2 antigens.
    Soulié JC; Devillier P; Santarelli J; Goudeau A; Vermeulen P; Guellier M; Saliou P; Hillion AM; Tron F; Huchet J
    Vaccine; 1991 Aug; 9(8):545-8. PubMed ID: 1837646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study on the comparative immunogenicity of a recombinant DNA hepatitis B vaccine containing pre-S components of the HBV coat protein with non pre-S containing vaccines.
    Yap I; Guan R; Chan SH
    J Gastroenterol Hepatol; 1995; 10(1):51-5. PubMed ID: 7620108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind dose-response study.
    Zuckerman JN; Sabin C; Craig FM; Williams A; Zuckerman AJ
    BMJ; 1997 Feb; 314(7077):329-33. PubMed ID: 9040320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis B third-generation vaccines: improved response and conventional vaccine non-response--third generation pre-S/S vaccines overcome non-response.
    Zuckerman JN
    J Viral Hepat; 1998 Nov; 5 Suppl 2():13-5. PubMed ID: 9857355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis B virus vaccination for older adults.
    Bennett RG; Powers DC; Remsburg RE; Scheve A; Clements ML
    J Am Geriatr Soc; 1996 Jun; 44(6):699-703. PubMed ID: 8642163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine.
    Shouval D; Roggendorf H; Roggendorf M
    Med Microbiol Immunol; 2015 Feb; 204(1):57-68. PubMed ID: 25557605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term immunogenicity safety and efficacy of a recombinant hepatitis B vaccine in healthy adults.
    Dentico P; Buongiorno R; Volpe A; Zavoianni A; Pastore G; Schiraldi O
    Eur J Epidemiol; 1992 Sep; 8(5):650-5. PubMed ID: 1426164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis B Virus Revaccination With Standard Versus Pre-S Vaccine in Previously Immunized Patients With Celiac Disease.
    Heshin-Bekenstein M; Turner D; Shamir R; Bar-Meir M; Dagan R; Zevit N; Silbermintz A
    J Pediatr Gastroenterol Nutr; 2015 Oct; 61(4):400-3. PubMed ID: 25988560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8-10-year-old children.
    Duval B; Gîlca V; Boulianne N; Deceuninck G; Rochette L; De Serres G
    Vaccine; 2005 Jul; 23(31):4082-7. PubMed ID: 15963363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody responses to recombinant, yeast-derived hepatitis B vaccine in teenage New Zealand children.
    Milne A; Moyes CD; Allwood GK; Pearce NE; Krugman S
    N Z Med J; 1988 Feb; 101(840):67-9. PubMed ID: 2967940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in renal pre-dialysis and dialysis patients.
    Gilbert CL; Stek JE; Villa G; Klopfer SO; Martin JC; Schödel FP; Bhuyan PK
    Vaccine; 2014 Nov; 32(48):6521-6. PubMed ID: 25252192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and safety of recombinant yeast-derived hepatitis B vaccine in haemodialysis patients.
    Fujiyama S; Yoshida K; Sato T; Shimada H; Deguchi T
    Hepatogastroenterology; 1990 Dec; 37 Suppl 2():140-4. PubMed ID: 2150664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Immunogenicity and harmlessness in the newborn of a vaccine (GenHevac B) containing the antigens S and pre-S2].
    Tron F; Soulié JC; Goudeau A; Devillier P; Saliou P
    Bull Soc Pathol Exot; 1991; 84(5 Pt 5):901-5. PubMed ID: 1840243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population.
    Jacques P; Moens G; Desombere I; Dewijngaert J; Leroux-Roels G; Wettendorff M; Thoelen S
    Vaccine; 2002 Nov; 20(31-32):3644-9. PubMed ID: 12399191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective clinical trial of hepatitis B vaccination in adults with and without type-2 diabetes mellitus.
    Van Der Meeren O; Peterson JT; Dionne M; Beasley R; Ebeling PR; Ferguson M; Nissen MD; Rheault P; Simpson RW; De Ridder M; Crasta PD; Miller JM; Trofa AF
    Hum Vaccin Immunother; 2016 Aug; 12(8):2197-2203. PubMed ID: 27123743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Anti-HBs persistence following primary vaccination with three doses of hepatitis B vaccine among normal and high-responder adults: a 3-year follow-up study].
    Lyu JJ; Zhang L; Yan BY; Liu JY; Feng Y; Song LZ; Chen SY; Zhou LB; Liang XF; Cui FQ; Wang FZ; Xu AQ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Jun; 50(6):478-83. PubMed ID: 27256725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity of a combined hepatitis A and B vaccine in healthy young adults.
    Knöll A; Hottenträger B; Kainz J; Bretschneider B; Jilg W
    Vaccine; 2000 Apr; 18(19):2029-32. PubMed ID: 10706965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age.
    Halperin SA; Ward B; Cooper C; Predy G; Diaz-Mitoma F; Dionne M; Embree J; McGeer A; Zickler P; Moltz KH; Martz R; Meyer I; McNeil S; Langley JM; Martins E; Heyward WL; Martin JT
    Vaccine; 2012 Mar; 30(15):2556-63. PubMed ID: 22326642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.